Screener
Summit Therapeutics SMMT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Other income, net | 5,788 | 3,938 |
| Net loss | $(189,424) | $(62,913) |
| Net loss per share: | ||
| Basic and diluted | $(0.24) | $(0.09) |
| Weighted average common shares outstanding: | ||
| Basic and diluted | 775,458,141 | 738,076,003 |
| Other comprehensive income (loss): | ||
| Foreign currency translation adjustments | 84 | (145) |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's EPS (diluted)?
- Summit Therapeutics (SMMT) reported EPS (diluted) of -$0.24 in Q1 2026.
- How has Summit Therapeutics's EPS (diluted) changed year-over-year?
- Summit Therapeutics's EPS (diluted) decreased by 166.7% year-over-year, from -$0.09 to -$0.24.
- What is the long-term trend for Summit Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Summit Therapeutics's EPS (diluted) has grown at a 20.6% compound annual growth rate (CAGR), from -$0.68 to -$1.44.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Summit Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude